GlassScriptPhysician profile
Sarah B Smith
NPI 1053639161
$2,202.85
in general payments reported to CMS, 2019-2025
26 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $58.65 · 2021: $33.73 · 2022: $239 · 2023: $100 · 2024: $590 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $310.41 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Apellis Pharmaceuticals, INC. | $267.66 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $259.85 | 2023-2025 | Eylea Hd, Eylea |
| New World Medical,INC. | $199.14 | 2022-2025 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Sun Pharmaceutical Industries INC. | $178.52 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $131.61 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $103.66 | 2025 | Veritas Vision System |
| Mallinckrodt Hospital Products INC. | $77.70 | 2024-2025 | Acthar |
| Astellas Pharma US INC | $76.35 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $62.20 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $53.68 | 2024 | Omidria, Rayner Cataract Set 1, Rayone Spheric |
| Oyster Point Pharma, INC. | $51.28 | 2022 | |
| Optos, INC. | $50.00 | 2022 | |
| Dompe US, INC. | $49.84 | 2024-2025 | Oxervate |
| Teva Pharmaceuticals USA, INC. | $47.14 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $43.08 | 2019 | |
| Allergan, INC. | $42.98 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $37.28 | 2024 | Xdemvy |
| Harrow Eye, LLC | $34.82 | 2025 | Triesence |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.46 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $19.95 | 2025 | Yutiq |
| Genentech USA, INC. | $19.09 | 2024 | Vabysmo |
| Horizon Therapeutics Plc | $18.75 | 2023 | Tepezza |
| Thea Pharma INC. | $14.90 | 2025 | Iyuzeh |
| Amgen INC. | $13.50 | 2025 | Tepezza |
| Biotissue Holdings INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.